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ABSTRACT — Knee pathologies including focal cartilage injuries, osteoarthritis (OA), and ligament injuries are common. The
poor regeneration and healing potential of cartilage has led to
the search for other treatment modalities with improved healing capacity. Furthermore, with an increasing elderly population that desires to remain active, the burden of knee pathologies
is expected to increase. Increased sports participation and the
desire to return to activities faster is also demanding more effective and minimally invasive treatment options. Thus, the use of
biologic agents in the treatment of knee pathologies has emerged
as a potential option. Despite the increasing use of biologic agents
for knee pathology, there are conflicting results on the efficacy of
these products. Furthermore, strong data supporting the optimal
preparation methods and composition for widely used biologic
agents, such as platelet-rich plasma (PRP) and bone marrow aspirate concentrate (BMAC), largely remain absent from the literature. This review presents the literature on the most commonly
employed biologic agents for the different knee pathologies.
■

Musculoskeletal diseases are particularly prevalent, with knee
pathology among the most common diseases (Schiller et al.
2012, Cross et al. 2014). These constitute both acute injuries
and degenerative diseases including osteoarthritis (OA). Specifically, between 1999 and 2008 the number of total knee
replacements due to OA in Scandinavia more than doubled
(Robertsson et al. 2010). This translates into an annual cost of
$462 billion dollars to the economy, secondary to lost wages
and the costs of treatment (Mather et al. 2013). An epidemiological study showed an annual incidence of 2.3 knee injuries

per 1,000 individuals (Gage et al. 2012). Another epidemiological study from Sweden reported that the incidence of knee
injuries resulting in a visit to the Emergency Department was
6 cases per 1,000 person years (Ferry et al. 2014).
In recent years, there has been increasing interest in the use
of orthobiologics for the treatment of several orthopedic conditions including focal cartilage injuries, early mild to moderate osteoarthritis, and soft tissue injuries (LaPrade et al. 2015,
2016, Zlotnicki et al. 2016). Orthobiologics are substances
that are naturally found in the human body, and are used
by orthopedic surgeons to improve the healing of cartilage,
injured muscles, tendons, ligaments, and fractures (Sampson et al. 2017). These include, among others, platelet-rich
plasma (PRP), bone marrow aspirate concentrate (BMAC),
and cell-derived therapies. These can be injected directly into
the injured structures such as muscle or tendon, or into the
knee joint for intraarticular pathologies. Even without many
clinical scientific studies, treatment with these agents in sports
medicine has also advanced the use of biologic agents in the
general population. Furthermore, there is a great desire for
athletes to return to pre-injury levels faster, further pushing
the use of these products. However, the cost of the development and application of these agents is high, and both have the
capacity to increase health care costs.
Despite the growing use of these biologic treatments, limited
strong evidence exists either citing the efficacy of the products
or providing guidelines for their standard of preparation. The
purpose of this review was to evaluate documentation on the
efficacy of the biologic treatments utilized in knee pathologies, including platelet-rich plasma (PRP), and bone marrow
aspirate concentrate (BMAC).

© 2017 The Author(s). Published by Taylor & Francis on behalf of the Nordic Orthopedic Federation. This is an Open Access article distributed under the terms
of the Creative Commons Attribution-Non-Commercial License (https://creativecommons.org/licenses/by-nc/3.0)
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Figure 1. Preparation of PRP. Following 1–2 spin cycles, three distinct
layers can be identified: red blood cells at the bottom, buffy coat containing white blood cells and platelets in the middle, and plasma on top.
The buffy coat is removed with a pipette and the plasma is isolated.

Platelet-rich plasma (PRP)
The use of PRP to treat sports medicine pathology of the knee
has rapidly expanded over the past decade. Classically, PRP
was defined as a volume of plasma that has a platelet count
“above baseline” during the early stages of clinical research
(Zhu et al. 2013). However, this definition has more recently
been refined to be more quantitative, requiring PRP to contain more than 1 million platelets per mL (Chahla et al. 2017)
of serum or 5 times the amount of baseline platelets (Dhillon et al. 2012). This elevated platelet count in PRP has been
suggested as necessary to stimulate targeted injured cells to
proliferate (Marx 2001, Rughetti et al. 2008). However, other
authors reported that increased platelet concentration beyond
the physiologic concentration did not improve functional graft
healing in an animal model (Fleming et al. 2015). The biological mechanism driving the clinical use of PRP involves
the action of local growth factors in PRP, which modify the
inflammatory response, and may affect cell proliferation and
differentiation (LaPrade et al. 2016).
Intra-articular PRP injections for the treatment of focal
chondral defects and early mild to moderate osteoarthritis
(OA) have been reported to reduce pain, while also improving range of motion and quality of life (Campbell et al. 2015)
(Figure 1).
Despite these promising results, most of the literature has
reported PRP to be beneficial only for a short period of time
(Dhillon et al. 2011). The recent systematic review by Campbell et al. (2015) assessed the clinically relevant improvements
after PRP treatment for knee osteoarthritis and found that
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intra-articular PRP injection was an effective treatment for up
to 12 months in radiographically evaluated, early-stage OA.
Several authors also observed a local adverse reaction, including local swelling and regional pain after serial PRP injections
(up to 4 injections), indicating that serial PRP injections to
increase effect over time may not be clinically feasible. To
evaluate the optimal leukocyte concentration in PRP, Riboh et
al. (2016) conducted a meta-analysis on all randomized control trials (RCTs) comparing the clinical outcomes and rates
of adverse reactions between leukocyte-poor (LP) and leukocyte-rich (LR) PRP for the treatment of knee OA. 3 RCTs
that used LP-PRP reported positive outcomes compared with
hyaluronic acid, while only 1 RCT using LR-PRP reported
positive effects versus hyaluronic acid (Riboh et al. 2016).
Although several uncontrolled studies have reported pain
reduction, functional improvement, and reduced prevalence
of surgical revisions and arthrofibrosis (Chahla et al. 2017),
further basic science evidence is necessary to determine the
effects, if any, of LP- or LR-PRP for intra-articular knee treatment and to evaluate whether one formulation yields superior
results.
In vivo anterior cruciate ligament (ACL) healing following PRP treatment has also been studied, with some studies
reporting improvement in ACL graft healing as measured
mechanically or with magnetic resonance image (Radice et
al. 2010, Vogrin et al. 2010, Cervellin et al. 2012). Conversely,
other studies have demonstrated no beneficial effects on ACL
healing when examining the same parameters (Murray et al.
2009, Nin et al. 2009). A recent systematic review of 11 randomized, controlled studies examined the use of PRP in ACL
reconstruction surgery (Figueroa et al. 2015). 6 of the 11 studies reported a faster graft maturation in the PRP group. 1 of 11
studies reported faster healing in the PRP group when examining tunnel widening. Finally, only 1 of the 11 studies reported
better clinical outcomes in the PRP group.
Identifying the specific components of PRP which could
be responsible for the improved clinical outcomes has been
elusive. Some authors noted that interleukin-1 (IL-1) and epidermal growth factor (EGF) stimulated meniscal stem cell
migration, while BMP and IGF-1 stimulated fibrochondrocyte
migration from the middle to avascular meniscal zones (Braun
et al. 2013). An analysis of PRP treatment trends from 2010 to
2011 indicated that 2,571 patients had received PRP injections
in these studies, with the greatest number being treated for
cartilage defects and meniscal injuries. Notably, PRP injection for ligamentous injuries made up only 7% of the total
PRP utilization (Zhang et al. 2016). Despite growing use of
PRP, there is a lack of standardized preparation protocols, and
variability of application of PRP for the various clinical conditions (Chahla et al. 2017).
In summary, several clinical studies have reported improvements in patient-reported outcomes and a significant reduction in pain scores following PRP treatment in damaged tissue
(Kon et al. 2013, Sundman et al. 2014), including tendons and
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early OA (Riboh et al. 2016). However, there is a paucity of
literature with a consistently used methodology to process
and activate these PRP formulations, making duplication of
similar clinical results after PRP therapy or comparison of the
effects of PRP on various musculoskeletal conditions between
studies challenging.
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Bone marrow aspirate concentrate (BMAC)
The use of intraarticular bone marrow aspirate concentrate
(BMAC) to treat various knee pathologies has recently grown
in popularity because it is one of the few approaches to deliver
progenitor cells that are currently approved by the United
States Food and Drug Administration (FDA) and that can be
performed in a single-stage procedure (Gobbi et al. 2015).
For BMAC, bone marrow is harvested and centrifuged to
isolate its cellular components in distinct layers and therefore it is considered to be minimally manipulated. This effectively concentrates the mononucleated cells (white blood
cells (WBCs), mesenchymal stem cells (MSCs), hematopoietic stem cells (HSCs), and platelets), in one layer and the
red blood cells in another. MSCs are of particular interest
because they are capable of self-renewal and differentiation
into mature muscle, bone, and cartilage (Fortier et al. 2010).
Despite comprising only 0.001–0.01% of cells in BMAC,
the MSCs that are present may play a role in healing through
homing capabilities that recruit more cells to the injury site
(Simmons and Torok–Storb 1991, Dar et al. 2005). MSCs’
regenerative potential, in conjunction with the ability to signal
the surrounding tissue to secrete growth factors that modulate the immune response and encourage regeneration at the
injury site, suggest that MSC presence provides BMAC with
potentially strong regenerative properties, even for avascular
tissues like articular cartilage. BMAC has also been reported
to contain increased levels of interleukin 1 receptor antagonist
(IL-1RA) and interleukin 1-beta (IL-1β), growth factors that
have critical roles in regeneration through immune response
modulation, in the joint space (Fortier et al. 2010, Oliver et
al. 2015).
Several groups have demonstrated that BMAC is not only
safe for patient use, but that it also has the potential to improve
pain and activity level in patients with various knee pathologies. Gobbi and Whyte (2016) demonstrated that, after receiving BMAC in a hyaluronic acid scaffold (HA-BMAC), all 50
patients with grade IV chondral lesions showed significantly
improved activity and pain outcome scores at 2 years followup, and each patient’s function was characterized as normal
or nearly normal at 5 years. In comparison, the same study
reported a decline in the percentage of patients with normal
or nearly normal knee function from two-thirds at 2 years to
only one-fourth at 5 years in patients who also had grade IV
chondral lesions but who received microfracture instead of
HA-BMAC. However, when microfracture was supplemented
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with a collagen membrane and BMAC, collagen matrix organization began to occur by 1-year follow-up in patients with
focal chondral lesions (Enea et al. 2015).
Findings from Krych et al. (2016) support these positive
outcomes by demonstrating that, in patients with grades III
and IV chondral lesions who were treated with an artificial
cartilage scaffold, patients receiving platelet-rich plasma
(PRP) or BMAC in addition showed more cartilage fill by
MRI after 1 year than patients who were treated with only the
control cartilage scaffold. However, only the BMAC group
showed MRI T2 relaxation values comparable to superficial
hyaline cartilage. Similarly, 22 of 25 active patients with
grade IV chondral lesions who received a cartilage scaffold
supplemented with BMAC showed integration of the scaffold, while 20 showed complete filling of their lesion by MRI
after 3 years.
Skowronski et al. (2013) found positive outcomes after
treating large chondral lesions with BMAC similar to Gobbi
and Whyte (2016), yet they also concluded that, for a similar population of patients with large chondral lesions, treatment with peripheral blood rather than BMAC yielded better
patient outcomes. A recent prospective, single-blind, placebocontrolled pilot study also found that, in patients with bilateral OA, BMAC injections provided after 6 months the same
amount of pain relief and increased activity level as saline
injected into the patient’s contralateral knee (Shapiro et al.
2017). The findings from this group need to be corroborated
by data from longer-term follow-up that includes MRI visualization of any changes in the cartilage structure, but these data
suggest that we do not understand the effects that BMAC has
on the knee. The studies cited in this review that are in favor
of BMAC’s use in the knee largely examined the effects of
BMAC in conjunction with a scaffold, while both Skowronski et al. (2013) and Shapiro et al. (2017) found negative and
inconclusive results after treating patients with BMAC alone.
Thus, despite the data in support of its use for various knee
pathologies, the field requires further basic science studies to
explain any mechanism of action, as well as strong randomized controlled trials.
Encouraging results have been presented also for patients
with moderate to severe osteoarthritis (OA), demonstrating
that BMAC injections improved functional activity scores and
pain scores (Centeno et al. 2014). Similarly, in patients with
chronic patellar tendinopathy, BMAC was found to significantly improve Tegner and International Knee Documentation
Committee (IKDC) scores 2 years post-injection (PascualGarrido et al. 2012). In a systematic review, which included
11 studies, Chahla et al. (2016) reported a lack of high-quality
studies despite growing interest in the use of BMAC. They
also reported that the use of BMAC was a safe procedure with
reported good results; however, there was a varying degree of
beneficial results after BMAC application with and without an
additional procedure for the treatment of chondral defects and
early stages of osteoarthritis.
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In summary, early basic science and clinical studies have
elucidated the benefits of BMAC for the treatment of knee
pathologies in both animal and human models. The ideal
number of BMAC treatments, the volume of treatment, and
the timing of injections for BMAC have not been well characterized. Patients with focal chondral defects who received a
single BMAC injection have been reported to have improved
outcomes (Gobbi et al. 2015). In patients with OA, improved
outcomes following BMAC injections have also been
reported; however, these studies utilized a variable number
of treatments and had limited follow-up intervals (Hauser and
Orlofsky 2013, Centeno et al. 2014, Kim et al. 2014). Finally,
and most importantly, further clinical studies are needed to
identify standardized preparation and application protocols to
protect and help patients.
Future directions
Despite the increasing and widespread use of biologic treatment agents in knee pathologies, there are still several areas of
controversy and a lack of documentation. There is still no consensus on the optimal protocol for preparing PRP and BMAC.
Thus, the products termed “PRP” and “BMAC” are produced
differently and have different compositions. It is therefore
difficult to compare outcome studies and to evaluate the efficacy of these agents. There is a need to standardize preparation protocols and composition of both PRP and BMAC.
There has been increasing interest in the use of scaffolds for
the treatment of focal chondral defects. Future research should
also evaluate the need for scaffolds in BMAC treatment, and,
if one is necessary, what the optimal scaffold is. Therefore,
designing optimal scaffolds with the best mechanical and biological properties to treat focal cartilage defects needs further
research.
Conclusions
While important advancements have been made in the field
of biologics, these therapies are still in their beginnings. In
order to advance the knowledge, it is important to first define
a minimal standard for each of these treatments and set a clear
nomenclature system for reporting. Furthermore, due to the
high number of variables that exists when processing these
compounds, it is important to characterize the preparation in
detail. While most studies suggest having good outcomes with
a relatively safe profile, they lack enough power and followup time for the evidence to be compelling. Future randomized
clinical trials with well-designed and defined protocols with
well-defined controls are needed in order to elucidate the real
efficacy of these therapies.
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